80 related articles for article (PubMed ID: 21080343)
21. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
23. [Establishment of RNA interfering retrovirus vector targeting CXCR4 gene driven by human prostate-specific antigen promoter and its biological effects on prostate cancer cells].
Du YF; Xing YF; Zeng FQ; Lu P; Liu XY; Xiao YJ
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):489-94. PubMed ID: 18069626
[TBL] [Abstract][Full Text] [Related]
24. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
25. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
26. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
27. Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors.
Athanassiadou P; Bantis A; Gonidi M; Liossi A; Aggelonidou E; Petrakakou E; Giannopoulos A
J Exp Clin Cancer Res; 2003 Dec; 22(4):613-8. PubMed ID: 15053304
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
30. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
Qi H; Fillion C; Labrie Y; Grenier J; Fournier A; Berger L; El-Alfy M; Labrie C
Cancer Res; 2002 Feb; 62(3):721-33. PubMed ID: 11830526
[TBL] [Abstract][Full Text] [Related]
31. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
32. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
33. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
34. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
35. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
36. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
[TBL] [Abstract][Full Text] [Related]
37. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma.
Perlino E; Lovecchio M; Vacca RA; Fornaro M; Moro L; Ditonno P; Battaglia M; Selvaggi FP; Mastropasqua MG; Bufo P; Languino LR
Am J Pathol; 2000 Nov; 157(5):1727-34. PubMed ID: 11073831
[TBL] [Abstract][Full Text] [Related]
38. Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors.
Federico A; Zappavigna S; Dallio M; Misso G; Merlino F; Loguercio C; Novellino E; Grieco P; Caraglia M
Curr Cancer Drug Targets; 2017; 17(2):109-121. PubMed ID: 27338741
[TBL] [Abstract][Full Text] [Related]
39. Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells.
Zappavigna S; Abate M; Cossu AM; Lusa S; Campani V; Scotti L; Luce A; Yousif AM; Merlino F; Grieco P; De Rosa G; Caraglia M
J Oncol; 2019; 2019():9293560. PubMed ID: 31929800
[TBL] [Abstract][Full Text] [Related]
40. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.
Balakan O; Kalender ME; Suner A; Cengiz B; Oztuzcu S; Bayraktar R; Borazan E; Babacan T; Camci C
Med Sci Monit; 2014 Aug; 20():1419-25. PubMed ID: 25112588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]